Axillary Dissection in Breast Cancer Patients with Metastatic Sentinel Node: To Do or Not to Do? Suggestions from Our Series by Bortolini, M. et al.
International Scholarly Research Network
ISRN Oncology
Volume 2011, Article ID 527904, 6 pages
doi:10.5402/2011/527904
Clinical Study
Axillary DissectioninBreast CancerPatients withMetastatic
SentinelNode:To Do orNot to Do? Suggestions from OurSeries
M. Bortolini,1 F. Genta,1 ChiaraPeronoBiacchiardi,1 E. Zanon,2
M. Camanni,1 andF.Deltetto1
1Ginteam, Mini-Invasive Gynaecological and Breast Unit, Evangelical Hospital, ASL TO1, Corso Marconi 35, 10125 Torino, Italy
2Breast Radiology Unit, Evangelical Hospital, ASL TO1, Torino, Italy
Correspondence should be addressed to F. Genta, markgen@libero.it
Received 10 April 2011; Accepted 20 May 2011
Academic Editor: C. Perez
Copyright © 2011 M. Bortolini et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Several studies have put to question and evaluated the indication and prognosis of sentinel lymph node biopsy (SNLB) as sole
treatment in human breast cancer. We reviewed 1588 patients who underwent axillary surgery. In 239 patients, axillary lymph
node dissection (ALND) was performed following positive ﬁne needle aspiration cytology (FNAC), and, in 299 cases, ALND was
executed after positive SNLB. The most dramatic result from our data is that patients with either micrometastasis of the sentinel
lymph node (SLN) or only metastatic SLN have, respectively, an 84.5% and a 75.0% chance of having no other nodal involvement.
We believe a more reﬁned patient selection is neccessary when considering ALND. Where the primary tumor is larger than 5cm,
where radio or adjuvant therapies are not indicated, in cases of FNAC+ nodes, and in cases presenting more than one metastatic
sentinel node, we prefer to carry out ALND. Having thus said, however, our data suggests that it is wise not to perform ALND in
almost all cases presenting positive SLNs.
1.Introduction
In1994,Giulianoandcolleaguespublishedtheoriginalstudy
concerning the feasibility and accuracy of intraoperative
sentinel lymph node biopsy (SLNB) [1]. Today, SLNB is
a widely accepted technique in the management of breast
cancer in patients with clinically negative axilla.
The literature in merit has since reported that less than
half of all patients who have undergone axillary lymph node
dissection (ALND) following a positive SLNB have shown
additional metastases [2]. Negative ALND patients did not
receive any therapeutic beneﬁt from the more invasive
procedure.InmicrometastaticSLNpatients,thefrequencyof
n o n - S L Nm e t a s t a s i si sl o w e r .A L N Do f t e nr e q u i r e sas e c o n d
surgical intervention and signiﬁes marked comorbidity,
including lymphedema, arm paresthesia, chronic pain, and
ad e c r e a s ei na r ma n ds h o u l d e rf u n c t i o ni n5t o5 0 %o f
patients. In contrast, SLNB has a much lower rate of comp-
lications [3].
Current guidelines from the National Comprehensive
Cancer Network (NCCN) [4] and the American Society
of Clinical Oncology (ASCO) [5] recommend ALND for
patientswhohaveSLNmetastases>0,2mm.OnlytheNCCN
addresses the possibility of avoiding ALND in patients with
favorable tumors or in patients destined to adjuvant therapy
when aﬀected by serious comorbidity conditions.
Veronesi published a study involving 516 breast cancer
patients treated with breast conserving surgery randomized
in two study groups: SLNB followed by ALND and SLNB
followed by ALND only when metastatic SLN were found. In
the ﬁrst group, 5% of patients with negative SLN were found
to have a false-negative SLN. In the second group, the same
rate of recurrence was expected. The observed cumulative
incidence of axillary recurrences in the second group who
did not receive ALND was found to be lower than 5% [6].
Several recent studies have suggested avoiding ALND in
selected patients [7, 8]. In 40 to 60% of patients, the SLN
is the only positive lymph node [9]. Several groups use nom-
ograms to assess the risk of nonsentinel node involvement in
thesepatients[10],whileotherinvestigatorsconsideraxillary
dissection necessary to ensure adequate locoregional control
[11].2 ISRN Oncology
The American College of Surgeons Oncology Group
Z0011 Randomized Trial included 891 patients and com-
pared locoregional recurrences and overall survival in SLN-
positive patients who did or did not undergo ALND [12].
Theydemonstratedthatthelocoregionalrecurrenceratesare
not improved by ALND after SLNB. They also reported that
ALND is not associated with improved survival in patients
with micro- or macrometastases in the SLNs.
Another substantial question is the postoperative treat-
ment planning. The AMAROS trial showed that the absence
of knowledge regarding the extent of nodal involvement
appears to have no major impact on the administration of
adjuvant therapy [13].
Other investigators note that approximately 50% of
patientshavenonsentinelnodemetastasesandarefavourable
to ALND which provides additional prognostic information
and decreases locoregional recurrences. Few studies found
additional positive nodes and distant recurrences in breast
cancerpatientswithmicrometastasisinSLNandsuggestthat
ALND with adjuvant therapy should be considered [14, 15].
The aim of this study is to determine, in our series, which
patients could have avoided ALND in cases of metastatic
sentinel lymph nodes. We underline that clinical evaluation
of axilla by ultrasounds (USs) and ﬁne needle aspiration
cytology(FNAC)wasnotthemethodofchoiceinmostcases.
2. Patientsand Methods
We conducted a retrospective review of 2180 cases of female
patients who had undergone breast cancer treatment in our
center between January 1, 2003, and February 28, 2011.
We excluded 592 records: 120 patients who had undergone
neoadjuvant therapy, 83 recurrences, 260 patients aﬀectedby
carcinoma in situ of the breast, 48 metastatic patients, and
81 “cup syndrome” patients or older patients who did not
receive any kind of axillary surgery. 1588 patients remained
eligible for the study.
SLNB wascarried out in patients negative in both clinical
and ultrasound axilla examination. In suspect cases, FNAC
was performed to assess the lymph node status.
SLNB was performed by means of an isotope injec-
tion with intraoperative detection via gamma probe. Lym-
phoscintigrams were executed in every patient. In cases of
radioactive node detection failure, a periareolar injection of
patent blue dye was performed. All stained or radioactive
lymph nodes were removed.
In most cases of positive micro- or macrometastatic
SLN, patients underwent ALND. Where SLN positivity was
described as isolated tumor cells (ITCs), ALND was not
considered. Most patients underwent ALND as a second,
delayed intervention. In cases of stain and radioactive
detection failure, immediate ALND was performed.
ALND denotes removal of the 1st and the 2nd levels of
axillary nodes. The 3rd nodal level is removed only when
clinically pathologic nodes are identiﬁed in the second level.
Patient records were fully documented in a proprietary
database which included registration of all data regard-
ing intervention, preoperative and postoperative histologic
diagnosis, number and status of lymph nodes removed,
Table 1: Pathologic ﬁndings after ALND in case of FNAC or SNB
positivity (we have higher lymph nodes involvement if FNAC is
positive; P<0.0001).
pN FNAC +
(%)
SLN +
All (%)
pN1mi
(sn) (%)
pN1a
(sn) (%)
1mi 2 80 80 —
0,8 26,8 84,2 —
1◦ 117 164 11 153
49 54,8 11,6 75
2a 73 38 3 35
30,5 12,7 3,2 17.2
3a 47 17 1 16
19,7 5,7 1 7,8
Total 239 299 95 204
pathologic TNM, and followup. Statistical distribution and
Pearson’s Chi-squared test were performed by EpiInfo soft-
ware.
3. Results
Toremovetheprimarytumor,abreast-conservingprocedure
was performed in 75.3% of patients and mastectomy was
performed on the remaining 24.7% of patients. Choice of
procedurewasdecidedpreoperativelybasedonclinicalgrou-
nds, and tumor specimens underwent routine laboratory
pathological study.
Meanpatientagewas60yearsold,andmedianfollow-up
time was 38 months.
Ameannumber of1.3SLNswereremovedduring SLNB,
and a mean number of 18.2 lymph nodes were removed
per ALND. Sentinel node detection rate in our series was
96.28%, combining radioactive and staining techniques. 57
patients were operated before 2005, when ASCO Guidelines
[6] suggested immediately ALND in breast cancer patients
with a presenting tumor greater than 3cm. In 48 patients,
the SLN was not identiﬁed, and in 40 of these patients ALND
was performed.
In 239 of the remaining 1483 women (16,1%), ultra-
sound axilla and FNAC showed metastatic disease. All
underwent immediate axillary dissection. In this set of
patients, we recorded 2 (0.8%) patients with pN1mi, 117
(49%) patients with pN1a, and 120 (50,2%) with pN2a or
pN3a (Table 1).
We reviewed a total of 1244 patients that underwent
ALND, recording frequencies of 3,7% of pT1mic (46), 5,9%
of pT1a (73), 20,4% of pT1b (254), 44,5% of pT1c (554),
22,7%ofpT2(282),and2,8%ofpT3andpT4(35)combined
(Table 2).
Of the 260 pTis patients, 116 SLNBs were executed
yielding 107 negative results, 5 not identiﬁed SLN, and 4 ITC
cases. None underwent ALND.
Of the 1244 SLNB patients, 299 (24%) underwent
delayed axillary dissection following diagnosis of sentinel
node metastases, 861 resulted negative SLN, and 84 SNLBISRN Oncology 3
Table 2: SLN involvement related to pT (higher pT is correlated
with higher chance of metastatic SLN, P<0.0001).
SLN-
(%)
SLN =
ITC
(%)
SLN =
pN1mi
(%)
SLN =
pN1a
(%)
Total∗
1 m i 4 1 4104 6
89,1 8,70 2,2 0
1a 63 7 2 1 73
86,3 9,6 2,7 1,4
1b 212 6 17 19 254
pT 83,5 2,4 6,7 7,5
1c 392 25 57 80 554
70,8 4,5 10,3 14,4
2 138 17 37 90 282
48,9 6,0 13,1 31,9
>21 51 1 1 83 5
42,8 2,9 2,9 51,4
861 60 115 208 1244
∗The sum of all pT1 cases is 927.
Table 3: Number of involved lymph nodes after ALND in case of
multiple positive SLNs (P<0.0001).
S L N + 1 234 5T o t a l
pN
pN1a 26 14 1 — — 41
pN2a 0 7 3 0 0 10
pN3a 0 2 0 1 1 4
55
positive for metastatic disease stopped their surgical path (60
ITC, 20 micrometastases, and 4 macrometastases).
115 patients presented micrometastases in their SLN,
and 208 patients presented metastases greater than 2mm.
In 80/95 patients after ALND stage pN1mi was conﬁrmed,
(84.2%), and 11/95 (11,6%) presented a deﬁnitive pN1a.
Only 4 patients had a deﬁnitive pN2a or pN3a. pN1a(sn)
patients presented 75% (153/204) of pN1a after ALND,
17,2% (35/204) of pN2a, and 7,8% (16/204) of pN3a
(Table 1).
In 55 cases where multiple SLNBs were removed, we
noticed a higher probability to have more severe deﬁnitive
staging with multiple positive SNLs (48,2%, 29/55; P<
0.0001) (Table 3).
Since FNAC is less sensitive than SLNB, FNAC selects
more advanced disease. In fact we noted a higher lymph
nodes involvement among the 239 FNAC selected patients
(Table 1).
927 patients presented mass of tumor <2cm, 77 of these
(8,3%) in resulted micrometastasis at SLNB. We noted 100
macrometastases in pT1 cases (10,1%).
Table 4: Histological type versus lymph node involvement.
Histologic type
n of SLN IDC % ILC % Others∗ Total
pT1
0 37
52,1
12
52,2 25 1
1 14
19,7
2
8,7 11 7
2 7
9,9
3
13 11 1
>2 13
18,3
6
25,1 12 0
pT2
Tot 71 23
0 21
39,6
12
36,4 33 6
1 17
32,1
6
18,2 02 3
2 2
3,8
4
12,1 06
>2 13
5
11
23 02 4
Tot 53 33
∗Others: histologic type as mucinous and tubular.
In 282 patients with pT2 staging where SLNB was exe-
cuted, we found 37 patients with micrometastases (13,1%)
and 90 pN1a (sn) patients (31,9%).
In 35 pT3 and pT4 patients, we found 1 micrometastasis
(2.9%) and 18 macrometastases (51,4%) (Table 2). The
direct relationship between poor lymph nodal status and
higher pT is obvious.
In 99 patients with pT1 and pN1a(sn) and 89 patients
with pT2 and pN1a(sn), all of whom underwent ALND, we
noted a higher incidence of patients with pT2 lobular cancer
to have multiple positive SLNs versus patients with ductal
cancer (P<0.005) (Table 4).
Following median followup of 38 months, we observed
9 axillary recurrences alone (ARA), 4 axillary recurrences
within regional recurrences (ARR), and 4 axillary recur-
rences within metastatic disease (ARM).
635 patients underwent ALND for varying therapeutic
strategies, none evidenced ARR, and 3 presented ARM.
Of the 861 negative SLN patients, we observed 14 with
recurrences (1,6%): 8 ARA, 3 ARR and 3 ARM (Table 5).
4. Discussion
SLNB for axillary staging has saved many breast cancer
patients from ALND and resultant complication, when the
SLN was found to be negative for metastatic disease. Know-
ing when to limit ALND is the objective of our discussion.
Recent data suggests avoiding ALND in cases of positive
SLN where treatment strategy includes whole breast radio-
therapy alone or combined with adjuvant therapy following
conservative surgery of T1-2 breast cancer.
Here, we open a wide area of discussion [8, 10].4 ISRN Oncology
Table 5: Axillary recurrences.
No. PTS ARA∗ ARR ARM Total %
No ALND
SLN- 861 8 3 3 14 1,6%
SLN = (ITC) 60 1 1 1 3 5,0%
SLN = pN1mi 20 0 0 0 0 —
SLN = pN1a 4 0 0 0 0 —
SLN not id 8 0 0 0 0 —
ALND
SLN = pN1mi 95 0 0 0 0 —
SLN = pN1a 204 0 0 1 1 0,5%
FNAC + 239 0 0 1 1 0,4%
SLN not id 40 0 0 0 0 —
SLN before 2005 57 0 0 1 1 1,8%
1588 9 4 7 22
∗ARA: axillary recurrences alone; ARR: axillary recurrences within regional recurrences; ARM: axillary recurrences within metastases.
Not indicating ALND in the forementioned patients
would by itself yield a mathematical advantage in patient
quality of life, but a ﬁne tuning selection of subgroups with
diﬀeringaxillaryinvolvementcouldbeworthstudy,asdiﬀer-
ing rates of axillary recurrence and mortality are expected.
Only clinically negative axillary patients are eligible for
SLNB. In most published studies, “clinical staging” consists
inclinicalexaminationalone[16].Today,bothUSandFNAC
are routinely used for preoperative evaluation of axilla [17].
The combined technologies are producing a selection of
FNAC-positive patients, who no longer need SLNB.
Our data shows that of the 239 patients that under-
went ALND following an FNAC positive SLN, a signiﬁ-
cantly higher frequency of axillary involvement (pN2a-3a)
(120/239, 50.2%) was observed in respect to FNAC-negative
patients where delayed ALND was performed as direct segue
to positive SLNB (55/299, 18.4%, P<0.0001).
If we consider FNAC-positive patients as clinically posi-
tive, they become eligible for ALND.
We would otherwise be accepting a risk of leaving
consistent residual axillary disease in 50% of the cases. it
may be in these cases where the literature shows that the
theoretical risk does not manifest recurrence.
Several conditions could explain such low rates of recur-
rence: immunologic systemic surveillance, subsequent radio
and adjuvant therapy, and lack of stem cells in axillary lymph
nodes to support cancer progression. The hypothetical risk,
however, could be higher in these patients [9, 18, 19].
Residual axillary disease in cases of positive SLNB that
could spare ALND would be only 18.4%. The use of pub-
lished nomograms [10] could work to further select sub-
groups of risk, rendering the choice to withhold ALND
easier.
Though our data evidenced increased lymph node
involvement directly related to tumor size, where tumors
range between 1 (pT1c) and 5 centimetres (pT2), the rates of
lymphnodeinvolvementarenotindicativeintheselectionof
patients who can safely avoid ALND (P<0.0001, Table 2).
While lobular type was associated with a greater nodal
involvement in case of T2 cancers, no histological variable
had signiﬁcant prognostic power in the selection of ALND
candidates (P<0.005, Table 4).
In cases of micrometastatic SLN it is evident, and our
data conﬁrms the literature in merit, that nodal involvement
is minimal to the point that omission of ALND is obvious
[20].
I no u rc o m p l e t es e r i e sw er e c o r d e d2 0a x i l l a r yr e c u r -
rences in 1588 patients. Three were part of the 635 patients
thatunderwentALND,eachoccurringinmetastaticpatients,
the remaining 17 axillary recurrences occurred among the
953 non-ALND patients. 14 of 861 were negative SLNB, and
3o f6 0w e r eS N L B - p o s i t i v eI T C .
It is worthwhile to consider that the omitted dissection
of the third nodal level does not imply an augmented risk of
recurrence.
In 115 micrometastatic SLNB patients (20 without
ALND) no axillary recurrences were recorded.
Since we accept the omission of 5% of positive non-
SLNs where SLNB is performed, we can accept both the
similar omission of 4.2% (4/179) in case of SLNs positive for
ITC or micrometastases and the worse condition in case of
macrometastasis in SLN: 51/204 (25%).
Where we found more than one metastatic SLN, we
observedafterALND14/29casesclassiﬁedaspN2aandpN3a
(48,2%), ﬁndings very similar to FNAC-positive patients.
These patients should be candidates for ALND.
The last subject of discussion is adjuvant therapy. The
AMAROS study [13] showed that knowledge of axillary
status did not modify postoperative treatment planning. Are
we sure that the same treatment would be chosen by all
oncologists and radiotherapists in so varying conditions like
positive SLNB and pN2a-3a after ALND [21]?ISRN Oncology 5
Do they all agree on extended ﬁelds of radiotherapy and
on taxanes administration for the patient presenting one
single positive SLN?
5. Conclusions
While continuing to perform ALND in cases of mastectomy,
nonplanned whole breast radiotherapy, non planned adju-
vant therapy, tumors larger than 5cm, FNAC-positive nodes,
and multiple positive SLNs, we propose a more prudential
selection of the remaining ALND candidates.
We suggest avoiding ALND in cases of micrometastatic
SLN and in all remaining positive SLNs.
Our data shows doing so would safely avoid a signiﬁcant
number of ALNDs.
We executed 578 ALNDs: 239 were FNAC+, 40 not
identiﬁed SLNs, 95 micrometastatic SLNs, and 204 were
macrometastatic SLNs on 136 breast conservative treatments
and 68 mastectomies. Twenty-nine presented multiple posi-
tive SLNs: 11 of these underwent concomitant breast conser-
vative treatment and 18 with concomitant mastectomy.
In retrospection, we could have avoided ALND in 95
micrometastatic SLNs and in 125 macrometastatic nonmul-
tiple SLNs with concomitant breast conservative treatment.
This translates to an sparing of 38% (220/578) among all
ALNDs or an avoidance of 64.8% (220/339) among SLNBs,
with a concomitant risk of 12.3% (27/220) of not surgically
treating residual axillary disease classiﬁed as pN2a or pN3a.
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